NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Citius Oncology, Inc. (CTOR) Stock Analysis

Citius Oncology, Inc. (CTOR) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CTOR

$0.70

+$0.03 (+4.37%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CTOR with… →

CTOR Key Statistics

As of Oct 21, 2026
Trading
Open
$0.71
Previous Close
$0.67
Day's Range
0.65–0.76
52-Week Range
0.49–1.93
Volume
22.89K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.40
Valuation
Market Cap
$74.06M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
10.42
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.48
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$24.76M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
105.76M
1-Year Return
−60.88%
Dividend and dates
Avg Volume
98.80K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CTOR closed at $0.70, −60.88% over 1 year.

Citius Oncology, Inc. (CTOR) has a market capitalization of $74.06M.

In fiscal 2025, CTOR reported revenue of $0.00.

CTOR Stock Return by Calendar Year

Citius Oncology, Inc. (CTOR) return since Dec 2022: what $10,000 became

1 year
$10,000 $3,912
−60.88%
3 years
$10,000 $646
−93.54%
Since Dec 2022
$10,000 $694
−93.06%

If you had invested $10,000 in Citius Oncology, Inc. (CTOR) at the close on December 8, 2022, the earliest close on record here, it would have been worth $694 at the close on October 21, 2026: −93.06% in total, −49.82% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−29.97%
2025−13.04%
2024−89.49%
2023+7.68%
2022 (partial year)+0.69%

As of October 21, 2026.

CTOR Revenue and Earnings by Fiscal Year

FY ends September
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$24.76M—
2024$0.00−$21.15M—
2023$0.00−$12.70M—
2022$0.00−$5.43M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$23.52M−$24.76M—
2024$0.00—−$20.57M−$21.15M—
2023$0.00—−$12.12M−$12.70M—
2022$0.00—−$4.86M−$5.43M—

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

CTOR Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricCTORDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio10.422.105.0x the median

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Citius Oncology, Inc. (CTOR) carries a market capitalisation of $74.06M. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry.

The most recent close on file for CTOR is $0.70, dated October 21, 2026. That is +$0.03 (+4.37%) against the previous close. Over the past 52 weeks the price has ranged from $0.49 to $1.93. The latest close sits 42.63% above that 52-week low.

Financial Health

In fiscal 2025, Citius Oncology, Inc. reported revenue of $0.00. The same year closed with a net loss of $24.76M. Trailing earnings per share are −0.48.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 10.42 times revenue. On price-to-sales that is 5 times the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

Over the trailing twelve months the total return is −60.88%. Measured over 3 years, that is −59.87% a year compounded. The reported beta is 3.4. Annualized volatility over the trailing 3 years is 163.1%.

Growth & Income

No dividend is on file for CTOR.

2026 is still running; the total return is −29.97% year to date. Across the complete calendar years on file, 2023 returned +7.68% and 2024 returned −89.49%. Of the 3 complete calendar years on file, 1 finished higher.

Peer Comparison

Citius Oncology, Inc. (CTOR) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Citius Oncology, Inc. CTOR $74.06M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Citius Oncology, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Citius Oncology, Inc.

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.

Visit website →